Identified 56 therapeutic activities of GSNO and GSNORis, including SPL-850 in ocular, autoimmune, neurodegenerative,
cardiovascular, respiratory, and metabolic disease.
Filed wide international patent rights for SPL-850 and related
molecules, claiming composition of matter in autoimmune, ocular, cardiovascular, and fibrotic diseases.
Clean safety data for SPL-850. Novel PK/PD for SPL-850 and active routes of administration: oral, topical, intravitreal, IP, IV.
Founder, Chairman, President, and Chief Technical Officer
Founder, Chief Executive Officer, and Chief Scientific Officer
Senior Vice President, Chemistry
Please reach out to us with any questions, inquiries, or requests for more information.
164 Saddleback Trl, Kalispell, Montana 59901, United States
office: 406-756-0240 cell: 301-332-0942 email: firstname.lastname@example.org